Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
EDIL3 is a strong and highly accurate diagnostic marker for breast cancer, meanwhile, EDIL3 overexpressed exosomes are novel biomarkers for the early diagnosis of triple-negative breast cancer (TNBC). Here, we proposed a fluorescent detection method for EDIL3 overexpressed exosomes, which is simple and sensitive. Basically, we utilized a magnetic nanospheres (MNS) based liquid sandwich immunoassay strategy. MNS were modified with CD63 aptamers, which can immunologically bound to the CD63 protein on the surface of exosomes. Alexa Fluor 647 labeled anti-EDIL3 antibodies (Anti-EDIL3/AF647) were used as the fluorescent probes to recognize the EDIL3 on exosomes derived from a TNBC cell line (MDA-MB-231). With the target TNBC exosomes present, sandwich structures containing MNS, exosomes and fluorescent probes were formed. After magnetic purification, optical super resolution imaging of the products was conducted to check the specificity of the assay. In addition, fluorescence signals of the products were detected to quantitatively analyze the EDIL3 overexpressed exosomes. The linear range was found to be 7.78 × 10to 7.78× 10particlesl. The detection limit was approximately 10 particlesl. The feasibility of the method for the detection of exosomes in complex biological samples was also demonstrated. Such a simple and sensitive detection method for EDIL3 overexpressed exosomes holds a great potential in clinical diagnosis of TNBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1088/1361-6528/ac805f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and functional characterization of hub genes CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets in thyroid cancer and Hashimoto's thyroiditis.
Clin Exp Med
May 2025
Department of Geriatrics, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, 415000, China.
In this study, we sought to identify key molecular players in both thyroid cancer (TC) and Hashimoto's thyroiditis (HT) by analyzing differentially expressed genes (DEGs) and their potential as biomarkers. We utilized datasets from the Gene Expression Omnibus (GEO) database and identified CLTA, EDIL3, HAPLN1, and HIP1 as hub genes common to both TC and HT. These genes were significantly upregulated in TC cell lines compared to normal controls, with high diagnostic accuracy as indicated by Receiver Operating Characteristic (ROC) curve analysis.
View Article and Find Full Text PDFNischarin inhibits the epithelial-mesenchymal transition process and angiogenesis in breast cancer cells by inactivating FAK/ERK signaling pathway via EGF like repeats and discoidin domains 3.
Mol Biol Rep
July 2024
Department of Oncology Surgery, Hangzhou Cancer Hospital, Yanguan Lane 34, Hangzhou, 310002, Zhejiang, China.
Article Synopsis
- NISCH is shown to have antitumor effects in breast cancer by reducing cell migration and invasion, with this study aiming to understand how it works.
- The study found that overexpressing NISCH decreased motility and colony formation in Hs578T cells and lowered EDIL3 mRNA levels while silencing NISCH in MDA-MB-231 cells produced opposite effects.
- Ultimately, NISCH inhibits the epithelial-mesenchymal transition and angiogenesis in breast cancer cells by down-regulating EDIL3, which inactivates the FAK/ERK signaling pathway, indicating potential new therapy strategies.
Key genes and molecular mechanisms related to Paclitaxel Resistance.
Cancer Cell Int
July 2024
Department of Biochemistry, Faculty of Science, University of Tabuk, Tabuk, 71491, Saudi Arabia.
Paclitaxel is commonly used to treat breast, ovarian, lung, esophageal, gastric, pancreatic cancer, and neck cancer cells. Cancer recurrence is observed in patients treated with paclitaxel due to paclitaxel resistance emergence. Resistant mechanisms are observed in cancer cells treated with paclitaxel, docetaxel, and cabazitaxel including changes in the target molecule β-tubulin of mitosis, molecular mechanisms that activate efflux drug out of the cells, and alterations in regulatory proteins of apoptosis.
View Article and Find Full Text PDFDel-1 Plays a Protective Role against COPD Development by Inhibiting Inflammation and Apoptosis.
Int J Mol Sci
February 2024
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Neutrophilic inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD). Developmental endothelial locus-1 (Del-1) has been reported to limit excessive neutrophilic inflammation by inhibiting neutrophil adhesion to the vascular endothelial cells. However, the effects of Del-1 in COPD are not known.
View Article and Find Full Text PDFEDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.
Cancer Immunol Res
November 2023
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Article Synopsis
- Immune checkpoint blockade (ICB) combined with antiangiogenic agents, like ipilimumab and bevacizumab, shows promise in treating solid tumors, and researchers are investigating how these treatment methods can work better together.
- In a study involving long-term responding patients, a strong antibody response to EDIL3, a protein linked to poor cancer prognosis, was found to correlate with positive treatment outcomes, highlighting its role in immune responses.
- Analysis suggests that cancer-associated fibroblasts (CAFs) may produce EDIL3, which impedes immune cell infiltration and contributes to immune exclusion, making EDIL3 a potential target for enhancing the effectiveness of cancer therapies.